Effect of artificial oxygen carrier with chemotherapy on tumor hypoxia and neovascularization.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D006224:Cricetinae; D006367:HeLa Cells; D006454:Hemoglobins; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy*; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000008:administration & dosage; D008647:Mesocricetus; D055806:Microvessels / Q000473:pathology; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000473:pathology* / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009593:Nitroimidazoles / Q000008:administration & dosage; D010100:Oxygen / Q000378:metabolism*; D010102:Oxygen Inhalation Therapy / Q000379:methods; D011092:Polyethylene Glycols; D047368:Tumor Burden / Q000187:drug effects
C497442:HIF1A protein, human; D006454:Hemoglobins; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D009593:Nitroimidazoles; D011092:Polyethylene Glycols; C033815:pimonidazole; D002945:Cisplatin; D010100:Oxygen